Welcome to our dedicated page for Cannabix Technol news (Ticker: BLOZF), a resource for investors and traders seeking the latest updates and insights on Cannabix Technol stock.
Cannabix Technologies Inc. develops marijuana and alcohol breath-testing technologies for workplace safety, law enforcement, and other safety-sensitive settings. Company news centers on the Marijuana Breath Test, or MBT, including its Breath Collection Unit and single-use Breath Cartridges used to collect breath samples for laboratory analysis of recent cannabis use.
Recurring updates include commercial rollout activity, deliveries through authorized resellers, product validation, regulatory and compliance testing for device hardware, and distribution or education efforts with testing-industry partners. News also covers the company’s work with Omega Laboratories on analytical methods for detecting cannabinoids in breath samples using LC-MS-based testing.
Cannabix Technologies continues to advance its marijuana breathalyzer technology, reporting progress in a comprehensive study conducted in the southern United States. The company’s FAIMS technology aims to detect THC in breath, correlating well with blood test results. Recent tests have demonstrated effective breath sample collection and analysis, eliminating traditional preparation steps and reducing costs. Cannabix seeks collaboration with law enforcement and other agencies to further develop these groundbreaking methods, while CEO Rav Mlait emphasizes their commitment to improving public safety.
Cannabix Technologies is advancing its marijuana breathalyzer technology aimed at enhancing public safety through detection of THC impairment. Participating in a multi-analysis study with law enforcement in the southern US, the company is using its proprietary Breath Collection Unit and MS Breath Sampler to analyze breath samples alongside traditional drug screening methods. The results of the study are anticipated to provide valuable data for regulators and law enforcement, supporting practical impairment identification.
Cannabix Technologies Inc. is advancing the development of marijuana breathalyzer devices aimed at enhancing public safety for law enforcement and employers. The company will present its research on the correlation of breath and blood cannabis levels at the Breath Summit 2022 in June. Their innovative technologies, including the THC Breath Analyzer, demonstrate promising results in detecting THC levels through breath samples, with rapid results and no sample preparation needed. Discussions with law enforcement are ongoing to test this hardware for practical applications.
Cannabix Technologies Inc. has successfully tested its marijuana breathalyzer technology, designed for law enforcement and workplace use, showing a strong correlation between THC levels in breath and blood plasma. This independent study, led by Dr. Phillip Olla, demonstrated that breath samples can be analyzed with Cannabix's handheld Breath Collection Unit and Mass Spectrometer within seconds, significantly reducing laboratory analysis times. The device, which requires no sample preparation, is in advanced prototype testing, aiming to enhance public safety by identifying recent marijuana use.
Cannabix Technologies has developed a Contactless Alcohol Breathalyzer (CAB) for vehicle cabins, responding to an inquiry from a major auto parts manufacturer. This prototype allows drivers to provide breath samples without a mouthpiece. The CAB technology could potentially be integrated into new safety standards mandated by the U.S. Infrastructure Investment and Jobs Act for impaired driving detection. While a provisional patent has been filed, the technology is still in preapproval stages, and no commercial sales are currently planned.
Cannabix Technologies Inc. (CSE: BLO, OTC PINK: BLOZF) is set to present its marijuana breathalyzer technology at the International Association for Chemical Testing (IACT) conference in mid-April 2022. Dr. Jared Boock will discuss THC Breath Testing Technology. The company has also shipped its new version 4.0 THC Breath Analyzers (THCBA) to beta sites for field testing. The THCBA can quickly and non-invasively test for recent THC use in under 5 minutes, enhancing safety for law enforcement and workplaces.
Cannabix Technologies is advancing marijuana breathalyzer technology aimed at enhancing public safety. At the Texas Impaired Driving Forum on February 23, 2022, Dr. Jared Boock showcased innovations in FAIMS-based detection methods for THC in breath samples. This technology could provide law enforcement with a non-invasive method for detecting recent marijuana use, addressing the growing issue of drugged driving. The Cannabix device is currently in advanced prototype and pre-clinical testing stages, with potential implications for law enforcement and employers concerned about impairment.
Cannabix Technologies Inc. has introduced its latest THC Breath Analyzer (THCBA) prototype, aimed at enhancing public safety by providing law enforcement and employers a tool for non-invasive marijuana testing. This new version incorporates design feedback to minimize variability and costs, with user testing already underway. The device can detect recent use of THC in under 5 minutes, making it more relevant than traditional methods. Planned field and clinical tests will establish benchmark standards for this innovative breath testing technology.
Cannabix Technologies Inc. is advancing marijuana breathalyzer technology for law enforcement and workplace settings. The Company will present at the Texas Impaired Driving Forum in February 2022, showcasing innovations in their THC breath analyzer devices. The version 4.0 THCBA is undergoing testing, demonstrating improved accuracy and reduced costs. Recent developments include a partnership with Dr. Richard Yost for FAIMS technology. As Germany prepares to legalize cannabis, Cannabix is exploring opportunities in this emerging market. The Company remains focused on ensuring public safety through its innovative solutions.
Cannabix Technologies is advancing its marijuana breathalyzer devices aimed at law enforcement and workplace safety. Recent tests have shown the FAIMS technology effectively isolates THC, providing important data on marijuana impairment. Engineers are working on making the device more portable and battery-powered, ensuring ease of use in the field. The technology aims to enable rapid, on-site testing of breath samples for THC detection, which could significantly enhance public safety by identifying recent cannabis use. The company is in advanced prototype and pre-clinical testing stages.